In the area of drug development and clinical pharmacotherapy, a profound understanding of
the pharmacokinetics and potential adverse reactions associated with the drug under …

Drug development for ischemic stroke is challenging as evidenced by the paucity of
therapeutics that have advanced beyond a phase III trial. There are many reasons for this …

Increasingly large cross-ancestry GWAS meta-analyses have discovered over 100
independent genetic risk loci harboring common single nucleotide variants associated with …

Antiplatelets and anticoagulants are extensively used in cardiovascular medicine for the
prevention and treatment of thrombosis in the venous and arterial circulations. Wide inter …

Disclaimer In an effort to expedite the publication of articles, AJHP is posting manuscripts
online as soon as possible after acceptance. Accepted manuscripts have been peer …

Aim: Understanding barriers and facilitators to pharmacogenomics (PGx) implementation
and how to structure a clinical program with the Veterans Health Administration (VA) …

Observational studies are notoriously susceptible to bias, and parallel-group randomized
trials are important to identify the best overall treatment for eligible patients. Yet, such trials …

Cardiovascular diseases (CVDs) remain one of the leading causes of morbidity and
mortality worldwide, with genetics being a major risk factor. Genetic cardiovascular disease …

Objective: We aimed to investigate the relationship between gene polymorphisms and the
occurrence of adverse clinical events following dual antiplatelet therapy in Patients with …

There is a large variability in warfarin dosage requirements. While some variability is related
to factors such as gender and age, a large number of intra-and interpatient variability is not …